Skip to main content
Donate

About Angelman Syndrome

AS Genotypes: Mutation

Angelman Syndrome Genotypes: Mutation (5-11% of individuals living with AS)

Some individuals live with AS because they have a difference within the UBE3A gene. As a reminder, a gene is an instruction to make a protein that the body needs. Each gene is made up of chemicals called nucleotides that form the DNA. The DNA nucleotides, called A, C, T, and G, are arranged in a very specific order that the cell reads to make the UBE3A protein. A difference in the DNA nucleotides is called a variant, also referred to as a mutation.

Graphic of a DNA, Gene, and Protein

The UBE3A gene has been found to have many different variants and different types of variants.   The table below provides an example of a gene as a sentence and then lists different types of variants to demonstrate how they can affect the gene.    

a Table showing different sequence variations for mutation.

Every individual who has a mutation in UBE3A is considered to have the Mutation genotype.  However, the different types of variants and different locations of variants within the UBE3A gene can affect the UBE3A protein in different ways, so there can be significant variability among individuals who are living with Mutation AS.  

My loved one has a UBE3A variant, but I am not sure what type of mutation he or she has.  How do I understand the report?

An image of a sample report from a sequencing test

Is Mutation AS inherited? 

UBE3A variants can be brand new in the egg that made the person, or they can be inherited from the mother who also carries the variant.  Consequently, testing the mother for the variant is important.  If the mother does not have the variant, the chance for a future child to have the UBE3A variant that causes AS is less than 1%.  This means that at least 99% of the time, future children will not have the UBE3A variant that causes AS.  The chance is not zero because there have been rare cases reported where the woman had multiple eggs with the variant or actually carried the variant in some of her body cells.  

If the mother has the UBE3A variant, each child has a 50% chance to inherit the UBE3A variant and therefore have AS, and each child has a 50% chance to inherit the mother’s other UBE3A gene (which is functional) and not have AS. If the mother has the variant, her siblings and other relatives may also have the variant.  They may consider genetic testing to understand the chances for their children.   

A flow chart describing testing for AS Mutation.

All the pharmaceutical companies in our space have stated that they want to have the most consistent group for the earliest phases of clinical trials (Phase 1/2), and in many cases they want the most severely affected to start with. That is generally considered deletions, but certain trials are also enrolling mutations. 

Two of the current clinical trials are enrolling individuals living with Mutation AS. Visit this page to learn more about them. 

Connect with other AS Mutation families by writing to us here: community@cureangelman.org.

Still have questions?

If you are wondering about your specific chance to have a child with a genetic variant that causes AS, it is very important to consult a genetics professional like a genetic counselor or geneticist. The chance varies depending upon the test results of the person living with AS and the testing that was performed on the parent(s). The information provided here may be helpful but it is not specific to your family and is not meant to replace genetic counseling.

Angelman Syndrome News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.